Immune checkpoint inhibitors (ICIs) have become a mainstay of cancer therapy, with over 80
FDA‐approved indications. Used in a variety of settings and in combination with each other …

The traditional picture of cancer patients as weak individuals requiring maximum rest and
protection is beginning to dissolve. Too much focus on the medical side and one's own …

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer and are now
the backbone of therapy for several malignancies. However, ICIs can cause a spectrum of …

Over the last 13 years, the use of immune checkpoint inhibitor (ICI) therapy has grown
remarkably, owing to their unprecedented anti-tumor efficacy in certain tumor groups. With …

Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, improving outcomes
for many patients. However, toxicities termed immune-related adverse events (irAEs) are …

Onconephrology is an upcoming and expanding subspecialty that deals with the
intersections between hematology/oncology and nephrology. With the paradigm shift in the …

Background The use of immune checkpoint inhibitors has altered therapeutic paradigms in
NSCLC. However, they may cause immune-related toxicities, including acute kidney injury …

ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have become a pillar of
treatment for numerous cancers with increasing use in combination with other ICIs and in …

Although immune checkpoint inhibitors (ICIs) have dramatically revolutionized the field of
oncology over the last decade, severe immune-related adverse events (irAEs) are …

Immune checkpoint inhibitors (ICIs) are now established treatments for advanced cancer
and their use is now ubiquitous. The high upside of ICIs is tempered by their toxicity profile …